HuGE Literature Finder
Records
1
-
30
| High WT1 expression predicted induction chemotherapy failure in acute myeloid leukemia patients with non-favorable cytogenetic risk. Clinical and experimental medicine 2023 1 . Xu Nan, Chen Wen-Min, Li Ling-Di, Long Ling-Yu, Wang Xu, Jiang Qian, Jiang Hao, Huang Xiao-Jun, Qin Ya-Zh |
| Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia 2023 2 . Mrózek Krzysztof, Kohlschmidt Jessica, Blachly James S, Nicolet Deedra, Carroll Andrew J, Archer Kellie J, Mims Alice S, Larkin Karilyn T, Orwick Shelley, Oakes Christopher C, Kolitz Jonathan E, Powell Bayard L, Blum William G, Marcucci Guido, Baer Maria R, Uy Geoffrey L, Stock Wendy, Byrd John C, Eisfeld Ann-Kathr |
| Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. American journal of hematology 2022 Aug . Lachowiez Curtis A, Reville Patrick K, Kantarjian Hagop, Jabbour Elias, Borthakur Gautam, Daver Naval, Issa Ghayas, Furudate Ken, Tanaka Tomoyuki, Pierce Sherry, Tang Guilin, Patel Keyur P, Medeiros Jeffrey, Abbas Hussein A, Haddad Fadi, Hammond Daniel, Short Nicholas J, Maiti Abhishek, Yilmaz Musa, Sasaki Koji, Takahashi Koichi, Pemmaraju Naveen, Konopleva Marina, Garcia-Manero Guillermo, Ravandi Farhad, Kadia Tapan M, Loghavi Sanam, DiNardo Courtney |
| Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis. Annals of hematology 2022 Jun . Shimony Shai, Canaani Jonathan, Kugler Eitan, Nachmias Boaz, Ram Ron, Henig Israel, Frisch Avraham, Ganzel Chezi, Vainstein Vladimir, Moshe Yakir, Aumann Shlomzion, Yeshurun Moshe, Ofran Yishai, Raanani Pia, Wolach Of |
| Survival prediction in acute myeloid leukemia using gene expression profiling. BMC medical informatics and decision making 2022 Mar 22 (1): 57. Lai Binbin, Lai Yanli, Zhang Yanli, Zhou Miao, OuYang Guifa |
| Association of genetic variants and survival in patients with acute myeloid leukemia in rural Appalachia. Cancer reports (Hoboken, N.J.) 2022 11 e1746. Shultz Carl, Gates Christopher, Petros William, Ross Kelly, Veltri Laruen, Craig Michael, Wen Sijin, Primerano Donald A, Hazlehurst Lori, Denvir James, Sdrimas Konstantin |
| Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia. Leukemia & lymphoma 2022 3 63 (8): 1956-1963. Fu Weijia, Huang Aijie, Xu Lili, Peng Yanni, Gao Lei, Chen Li, Chen Jie, Tang Gusheng, Yang Jianmin, Ni Xio |
| Ferroptosis-related gene signature predicts the clinical outcome in pediatric acute myeloid leukemia patients and refines the 2017 ELN classification system. Frontiers in molecular biosciences 2022 8 9 954524. Tao Yu, Wei Li, You H |
| Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia. Journal of internal medicine 2022 10 293 (3): 329-339. Weng Guangyang, Zhang Yu, Yu Guopan, Luo Tingyue, Yu Sijian, Xu Na, Sun Zhiqiang, Lin Dongjun, Deng Lan, Liang Xinquan, Xiao Jie, Zhang Hongyu, Guo Ziwen, Shao Ruoyang, Du Xin, Jin Hua, Liu Qi |
| Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. American journal of hematology 2022 1 97 (3): 329-337. Reville Patrick K, Sasaki Koji, Kantarjian Hagop M, Daver Naval G, Yilmaz Musa, Dinardo Courtney D, Short Nicholas J, Borthakur Gautam, Pemmaraju Naveen, Mehta Rohtesh S, Pierce Sherry, Konoplev Sergej N, Khoury Joseph D, Garcia-Manero Guillermo, Konopleva Marina Y, Jabbour Elias, Ravandi Farhad, Kadia Tapan |
| No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group. Disease markers 2022 9 2022 3132941. Castaño-Bonilla Tamara, Barragán Eva, Sargas Claudia, Sanz Alejandro, Algarra Lorenzo, Herrera-Puente Pilar, García-Boyero Raimundo, Barrios Manuel, Martinez-Cuadron David, Rodriguez-Veiga Rebeca, Boluda Blanca, Gil Cristina, Serrano-López Josefina, Martínez-López Joaquín, Sayas-Lloris María José, Olave María Teresa, Riaza-Grau Rosalía, Castillo Teresa Bernal-Del, Larrayoz María José, Amigo Raquel, Jiménez-Velasco Antonio, Sánchez Joaquín, Ayala Rosa, Blas Carlos, Lainez Daniel, Serrano-López Juana, Sanz Miguel A, Alonso-Domínguez Juan M, Montesinos P |
| Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood cancer journal 2022 12 12 (12): 170. Jentzsch Madlen, Bischof Lara, Ussmann Jule, Backhaus Donata, Brauer Dominic, Metzeler Klaus H, Merz Maximilian, Vucinic Vladan, Franke Georg-Nikolaus, Herling Marco, Platzbecker Uwe, Schwind Sebasti |
| Real-life challenges using personalized prognostic scoring systems in acute myeloid leukemia. Cancer medicine 2022 11 . Calleja Anne, Loschi Michael, Bailly Laurent, Morisot Adeline, Marceau Alice, Mannone Lionel, Robert Guillaume, Auberger Patrick, Preudhomme Claude, Raynaud Sophie, Subtil Fabien, Sujobert Pierre, Cluzeau Thom |
| The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients. Frontiers in oncology 2022 12 12 1054458. Villar Sara, Ariceta Beñat, Agirre Xabier, Urribarri Aura Daniela, Ayala Rosa, Martínez-Cuadrón David, Bergua Juan Miguel, Vives Susana, Algarra Lorenzo, Tormo Mar, Martínez Pilar, Serrano Josefina, Simoes Catia, Herrera Pilar, Calasanz Maria José, Alfonso-Piérola Ana, Paiva Bruno, Martínez-López Joaquín, San Miguel Jesús F, Prósper Felipe, Montesinos P |
| Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. Clinical lymphoma, myeloma & leukemia 2021 Oct . Ambinder Alexander, Smith Matthew, Tsai Hua-Ling, Varadhan Ravi, DeZern Amy, Dalton William, Gocke Christian, Webster Jonathan, Gondek Lukasz, Gojo Ivana, Ali Syed Abbas, Huff Carol Ann, Swinnen Lode, Wagner-Johnston Nina, Showel Margaret, Prince Gabrielle, Borrello Ivan, Bolaños-Meade Javier, Luznik Leo, Jain Tania, Imus Philip, Fuchs Ephraim, Ambinder Richard, Gladstone Douglas E, Levis Mark, Jones Richard, Ghiaur Gabriel, Smith B Dougl |
| Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations. Hematology (Amsterdam, Netherlands) 2021 (1): 340-347. Zhou Lili, An Jingnan, Hou Chang, Ding Zixuan, Qiu Huiying, Tang Xiaowen, Sun Aining, Chen Suning, Xu Yang, Liu Tianhui, Wu Dep |
| A clinically applicable gene expression-based score predicts resistance to induction treatment in acute myeloid leukemia. Blood advances 2021 9 5 (22): 4752-4761. Moser Christian, Jurinovic Vindi, Sagebiel-Kohler Sabine, Ksienzyk Bianka, Batcha Aarif M N, Dufour Annika, Schneider Stephanie, Rothenberg-Thurley Maja, Sauerland Cristina M, Görlich Dennis, Berdel Wolfgang E, Krug Utz, Mansmann Ulrich, Hiddemann Wolfgang, Braess Jan, Spiekermann Karsten, Greif Philipp A, Vosberg Sebastian, Metzeler Klaus H, Kumbrink Jörg, Herold Tobi |
| Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. European journal of haematology 2021 5 107 (3): 343-353. Ngai Lok Lam, Ma Connie Y, Maguire Orla, Do An D, Robert Alberto, Logan Aaron C, Griffiths Elizabeth A, Nemeth Michael J, Green Cherie, Pourmohamad Tony, van Kuijk Bo J, Snel Alexander N, Kwidama Zinia W, Venniker-Punt Bianca, Cooper James, Manz Markus G, Gjertsen Bjørn T, Smit Linda, Ossenkoppele Gert J, Janssen Jeroen J W M, Cloos Jacqueline, Sumiyoshi Tei |
| European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood advances 2021 12 6 (4): 1193-1206. Bataller Alex, Garrido Ana, Guijarro Francesca, Oñate Guadalupe, Diaz-Beyá Marina, Arnan Montserrat, Tormo Mar, Vives Susana, de Llano María Paz Queipo, Coll Rosa, Gallardo David, Vall-Llovera Ferran, Escoda Lourdes, Garcia-Guiñon Antonio, Salamero Olga, Sampol Antònia, Merchan Brayan M, Bargay Joan, Castaño-Díez Sandra, Esteban Daniel, Oliver-Caldés Aina, Rivero Andrea, Mozas Pablo, López-Guerra Mònica, Pratcorona Marta, Zamora Lurdes, Costa Dolors, Rozman Maria, Nomdedéu Josep F, Colomer Dolors, Brunet Salut, Sierra Jorge, Esteve Jor |
| Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood advances 2021 8 5 (17): 3279-3289. Stasik Sebastian, Eckardt Jan-Niklas, Kramer Michael, Röllig Christoph, Krämer Alwin, Scholl Sebastian, Hochhaus Andreas, Crysandt Martina, Brümmendorf Tim H, Naumann Ralph, Steffen Björn, Kunzmann Volker, Einsele Hermann, Schaich Markus, Burchert Andreas, Neubauer Andreas, Schäfer-Eckart Kerstin, Schliemann Christoph, Krause Stefan, Herbst Regina, Hänel Mathias, Frickhofen Norbert, Noppeney Richard, Kaiser Ulrich, Baldus Claudia D, Kaufmann Martin, Rácil Zdenek, Platzbecker Uwe, Berdel Wolfgang E, Mayer Jiri, Serve Hubert, Müller-Tidow Carsten, Ehninger Gerhard, Bornhäuser Martin, Schetelig Johannes, Middeke Jan M, Thiede Christian, |
| Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. Journal of hematology & oncology 2021 7 14 (1): 107. Bill Marius, Mrózek Krzysztof, Giacopelli Brian, Kohlschmidt Jessica, Nicolet Deedra, Papaioannou Dimitrios, Eisfeld Ann-Kathrin, Kolitz Jonathan E, Powell Bayard L, Carroll Andrew J, Stone Richard M, Garzon Ramiro, Byrd John C, Bloomfield Clara D, Oakes Christopher |
| Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification. Blood advances 2021 8 5 (17): 3254-3265. van der Werf Inge, Wojtuszkiewicz Anna, Meggendorfer Manja, Hutter Stephan, Baer Constance, Heymans Martijn, Valk Peter J M, Kern Wolfgang, Haferlach Claudia, Janssen Jeroen J W M, Ossenkoppele Gert J, Cloos Jacqueline, Haferlach Torst |
| Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. Blood advances 2020 Aug 4 (16): 3864-3874. Grimm Juliane, Jentzsch Madlen, Bill Marius, Goldmann Karoline, Schulz Julia, Niederwieser Dietger, Platzbecker Uwe, Schwind Sebasti |
| Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood advances 2020 May 4 (9): 1942-1949. Gardin Claude, Pautas Cécile, Fournier Elise, Itzykson Raphaël, Lemasle Emilie, Bourhis Jean-Henri, Adès Lionel, Marolleau Jean-Pierre, Malfuson Jean-Valère, Gastaud Lauris, Raffoux Emmanuel, Lambert Juliette, Braun Thorsten, Thomas Xavier, Chantepie Sylvain, Cluzeau Thomas, de Botton Stéphane, Berthon Céline, Boissel Nicolas, Duployez Nicolas, Terré Christine, Peffault de Latour Régis, Michallet Mauricette, Celli-Lebras Karine, Preudhomme Claude, Dombret Her |
| Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged?<60 years. Leukemia 2020 May . Eisfeld Ann-Kathrin, Kohlschmidt Jessica, Mims Alice, Nicolet Deedra, Walker Christopher J, Blachly James S, Carroll Andrew J, Papaioannou Dimitrios, Kolitz Jonathan E, Powell Bayard E, Stone Richard M, de la Chapelle Albert, Byrd John C, Mrózek Krzysztof, Bloomfield Clara |
| Acidic leucine-rich nuclear phosphoprotein-32A expression contributes to adverse outcome in acute myeloid leukemia. Annals of translational medicine 2020 5 8 (6): 345. Huang Sai, Huang Zhi, Ma Chao, Luo Lan, Li Yan-Fen, Wu Yong-Li, Ren Yuan, Feng Co |
| Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. Cancers 2020 12 13 (1): . Minetto Paola, Candoni Anna, Guolo Fabio, Clavio Marino, Zannier Maria Elena, Miglino Maurizio, Dubbini Maria Vittoria, Carminati Enrico, Sicuranza Anna, Ciofini Sara, Colombo Nicoletta, Pugliese Girolamo, Marcolin Riccardo, Santoni Adele, Ballerini Filippo, Lanino Luca, Cea Michele, Gobbi Marco, Bocchia Monica, Fanin Renato, Lemoli Roberto Massi |
| Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A. Proceedings of the National Academy of Sciences of the United States of America 2020 10 117 (42): 26340-26346. Bill Marius, Mrózek Krzysztof, Kohlschmidt Jessica, Eisfeld Ann-Kathrin, Walker Christopher J, Nicolet Deedra, Papaioannou Dimitrios, Blachly James S, Orwick Shelley, Carroll Andrew J, Kolitz Jonathan E, Powell Bayard L, Stone Richard M, de la Chapelle Albert, Byrd John C, Bloomfield Clara |
| Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia 2020 4 34 (12): 3161-3172. Herold Tobias, Rothenberg-Thurley Maja, Grunwald Victoria V, Janke Hanna, Goerlich Dennis, Sauerland Maria C, Konstandin Nikola P, Dufour Annika, Schneider Stephanie, Neusser Michaela, Ksienzyk Bianka, Greif Philipp A, Subklewe Marion, Faldum Andreas, Bohlander Stefan K, Braess Jan, Wörmann Bernhard, Krug Utz, Berdel Wolfgang E, Hiddemann Wolfgang, Spiekermann Karsten, Metzeler Klaus |
| Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood 2019 12 135 (8): 542-546. Fournier Elise, Duployez Nicolas, Ducourneau Benoît, Raffoux Emmanuel, Turlure Pascal, Caillot Denis, Thomas Xavier, Marceau-Renaut Alice, Chantepie Sylvain, Malfuson Jean-Valère, Lemasle Emilie, Cheok Meyling, Celli-Lebras Karine, Guerin Estelle, Terré Christine, Lambert Juliette, Pautas Cécile, Dombret Hervé, Castaigne Sylvie, Preudhomme Claude, Boissel Nicol |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 28, 2023
- Content source: